Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.5 million.

  • bioAffinity Technologies' Free Cash Flow fell 4410.5% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year decrease of 1702.2%. This contributed to the annual value of -$7.3 million for FY2024, which is 2117.19% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Free Cash Flow of -$2.5 million as of Q3 2025, which was down 4410.5% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Free Cash Flow registered a high of -$376141.0 during Q2 2022, and its lowest value of -$2.7 million during Q2 2025.
  • For the 4-year period, bioAffinity Technologies' Free Cash Flow averaged around -$1.6 million, with its median value being -$1.6 million (2023).
  • In the last 5 years, bioAffinity Technologies' Free Cash Flow crashed by 26257.95% in 2023 and then surged by 2910.33% in 2025.
  • bioAffinity Technologies' Free Cash Flow (Quarter) stood at -$1.3 million in 2022, then fell by 23.24% to -$1.6 million in 2023, then fell by 4.64% to -$1.7 million in 2024, then crashed by 47.67% to -$2.5 million in 2025.
  • Its Free Cash Flow stands at -$2.5 million for Q3 2025, versus -$2.7 million for Q2 2025 and -$1.7 million for Q1 2025.